ILCA School of Liver Cancer Virtual 2020

HomeEducationILCA School of Liver Cancer Virtual 2020

Scientific Education

A Unique Learning Platform

The ILCA School of Liver Cancer aims at delivering scientific education and helping progress ILCA’s mission to advance research in pathogenesis, prevention and treatment of liver cancer.

The ILCA School is a unique learning platform for practitioners and investigators to receive education in an intense, interactive and multidisciplinary format.

This annual educational event consists of 1,5 day courses focusing on a specific topic and is hosted in a Centre of Excellence worldwide which is selected based on application.

The ILCA School provides fellows in gastroenterology, hepatology, basics/transitional researchers and other liver cancer related professionals an opportunity to enhance their scientific experience by attending a multidisciplinary programme delivered by the most eminent international liver cancer specialists.

Participants learn about the principles and nuances of the diagnosis, management, and clinical investigation of liver cancer. The School’s intense, multidisciplinary and interactive format offers attendees state-of-the-art clinically relevant information regarding the disease.

Educational format
  • A residential, didactic and interactive format
  • Dedicated time for one on one exchanges with a distinguished faculty and key opinion leaders
  • A balanced seminar format involving multidisciplinary faculty
  • Case-based examples for discussion emphasis
Who should attend?

Fellows in gastroenterology and hepatology training programmes, junior faculty, basic/translational researchers and experienced clinicians with a desire to become more involved in liver cancer investigation and care.

Events

ILCA School 2020

The next ILCA School of Liver Cancer will be virtual this December!

ILCA is very pleased to announce that the next edition of the ILCA School of Liver Cancer will be virtual this December 2020.

The ILCA School provides fellows in gastroenterology, hepatology, basics/transitional researchers and other liver cancer-related professionals an opportunity to enhance their scientific experience by attending a multidisciplinary programme delivered by the most eminent international liver cancer specialists.

Sign today and join to get the deepest knowledge on:

  • Understanding the pathogenesis of hepatocellular carcinoma and how to translate this knowledge in clinical practice
  • Knowing the effect of antiviral treatment on the natural history of HCC
  • Understanding the place of curative treatments (transplantation, resection and ablation) in management of early HCC
  • Describing how radiology could help for the diagnosis and the assessment of the radiological response of HCC
  • Defining the role of pathology in HCC management
  • Discussing the evidence about SIRT and tyrosine kinase inhibitors in advanced HCC
Programme

Friday, 11 December
Risk factors, screening and diagnosis of HCC: What is new?
(Chair: Valérie Paradis, Beaujon)
08:25 – 08:30 Opening Remarks

Jean-Charles Nault (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris), Eric Vibert (Paul Brousse hospital, Villejuif, APHP): closing remarks

08:30 – 08:45 The hepatocellular carcinoma session

Risk factors, screening and diagnosis of HCC: What is new?

Nathalie Ganne-Carrie (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris): Perspective on epidemiology and HCC screening in the era of NASH

08:45 – 09:00 Understanding the physiopathology of NASH related HCC

Mathias Heikenwalder (Heidelberg, DKFZ)
09:00 – 09:15 Update on the Imaging Diagnosis of HCC

Alain Luciani (Mondor Hospital, Créteil, APHP)

09:15 – 09:30 The future of HCC pathology

Julien Calderaro (Mondor Hospital, Créteil, APHP)

09:30 – 10:00 Blast session on hot topics: controversies in HCC screening and diagnosis (two 10 minute presentations + 10 minute discussion)

Pierre Nahon (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris):  Impact of antiviral treatment on tumor occurrence and recurrence

François Durand (Beaujon Hospital, Clichy, APHP): Why and how to assess non-tumor liver in HCC patients?

10:00 – 10:30 Virtual Coffee Break
Early HCC: can we go beyond guidelines?
(Chair: Michel Beaugrand, Bobigny)
10:30 – 10:45 Sandra Rebouissou (Cordeliers research center, Paris): Preclinical models of HCC and prediction of therapeutic response
10:45 – 11:00 Eric Vibert (Paul Brousse hospital, Villejuif, APHP): Why and how to expend criteria for surgery?
11:00 – 11:15 Olivier Seror (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris): Current knowledge and innovation in percutaneous treatment of HCC
11:15 – 11:30 Blast session on hot topic: can we improve treatment of early HCC?

Olivier Scatton (Pitié-Salpétrière Hospital, Paris, APHP): The place of mini invasive surgery : short term advantages and bridge to liver transplantation

Christophe Duvoux (Mondor Hospital, Créteil, APHP): Can we expend criteria of liver transplantation beyond composite criteria ? (blast session: 2 X 10 mn presentation + 10 mn discussion)

11:30 – 12:00 Break
Evidence and doubt about management of Intermediate HCC
Chair: Gregory Gores, Mayo Clinic
12:00 – 12:15 Thierry De Baere (Institut Gustave Roussy, Villejuif): Current knowledge of endovascular treatment of HCC (except SIRT)
12:15 – 12:30 Maxime Ronot (Beaujon Hospital, Clichy, APHP): Assessment of radiological response: conventional and functional imaging of HCC
12:30 – 13:00 Blast session on hot topics: role of SIRT in 2020

Boris Guiu (CHU Montpellier): SIRT Pro

Tim Meyer (Royal Free Hospital, London): SIRT Against (blast session: 2 X 10 mn presentation followed by 10 mn discussion)

13:00 – 14:00 Lunch
14:00 – 14:15 State of the art: Jessica Zucman-Rossi (Cordeliers research center, Paris) Genomic of hepatocellular carcinoma 
Present and future of advanced HCC: immunotherapy
(Chair: Sandrine Faivre, Saint Louis Hospital)
14:15 – 14:30 Amaia Lujambio (USA): liver immunology and HCC for the dummies
14:30 – 14:45 Thomas Decaens (CHU Grenoble): immunotherapy of HCC hope and hype
14:45 – 15:15 Blast session on hot topics: new questions rise with immunotherapy

Stéphane Champiat (Institut Gustave Roussy, Villejuif): Can we identify predictor of response to immunotherapy? The immuno-oncologist point of view

Mohamed Bouattour (Beaujon Hospital, Clichy, APHP): management of adverse events of immunotherapy 

Saturday, 12 December
Present and future of advanced HCC: targeted therapy
(Chair: Tim Meyer, Royal Free Hospital)
15:30 – 15:45 Augusto Villanueva (Mount Sinai Hospital, New-York): Non-invasive biomarkers in HCC
15:45 – 16:00 Peter Galle (University Medical Center, Mainz): current and future role of targeted therapy in the management of advanced HCC
16:00 – 16:30 Blast session on hot topics: improving results of targeted therapy

Olivier Rosmorduc (Paul Brousse hospital, Villejuif, APHP): Potential role of combination therapy in HCC

Sandrine Faivre (Saint Louis Hospital, Paris, APHP): Reason of failure and success of phase 3 randomized controlled trial

16:30 – 16:45 State of the Art: Pr Jordi Bruix Classification and treatment of HCC: a historical perspective
Clinical case: round of discussion
09:00 – 09:30 Early HCC

A multidisciplinary approach of a case (Panel: Daniel Cherqui, Valérie Paradis, Olivier Seror, Jordi Bruix)

Presentation of case report Manon Allaire (Pitié-Salpétrière, Paris, APHP): A small HCC with aggressive features

09:30 – 10:00 A multidisciplinary approach of a case (Panel: Eric Vibert, Thierry De Baere, Sandrine Faivre, Olivier Rosmorduc)

Presentation of case report Marie Lequoy (Saint Antoine hospital, Paris, APHP): cholangiocarcinoma

10:00 – 10:30 A multidisciplinary approach of a case (Panel: René Adam, Valérie Vilgrain, Christophe Duvoux, Jean Charles Nault)

Presentation of case report Giuliana Amaddeo (Mondor Hospital, Créteil, APHP): An intermediate HCC

10:30 – 11:00 Break
11:00 – 11:15 Lars Zender (University of Tubingen) Pathogenesis of cholangiocarcinoma and cell of origin
11:15 – 11:30 Valérie Paradis (Beaujon Hospital, Clichy, APHP): primary liver cancers and mixed tumors: a continuum? the molecular biologist/pathologist point of view
11:30 – 11:45 Julien Edeline (Centre Eugène Marquis, Rennes) Systemic treatment of cholangiocarcinoma: to a personalized medicine
11:45 – 12:00
Blast session on hot topics: what is the best option for curative treatment of intrahepatic and extrahepatic cholangiocarcinoma?
Olivier Soubrane (Beaujon Hospital, Clichy, APHP): Resection
Emmanuel Boleslaswki (Hôpital Huriez, CHU Lille): Transplantation
Registration

Registrations for the ILCA School of Liver Cancer 2020 are now open.

Venue

The ILCA School of Liver Cancer 2020 will take place virtually.

Grant

The ILCA School of Liver Cancer is supported by an unrestricted educational grant from Bristol-Myers Squibb

Copyright © Society For Clinical Data Management. All Rights Reserved
appstore